About Nicole Luosey

This author has not yet filled in any details.
So far Nicole Luosey has created 8 blog entries.

Cadent Therapeutics to Participate in Upcoming Investor Conferences

By |2020-06-29T12:15:02+00:00June 29th, 2020|

CAMBRIDGE, Mass., June 29, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that management will participate in the following upcoming virtual investor conferences:

Cadent Therapeutics to Present at the Jefferies Healthcare Conference

By |2020-05-27T20:20:04+00:00May 27th, 2020|

CAMBRIDGE, Mass., May 27, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2:00-2:25 pm ET. The conference will be held in a virtual meeting format.

Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing

By |2020-04-29T12:22:58+00:00April 29th, 2020|

CAMBRIDGE, Mass., April 29, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced today that it has closed the $15 million final equity tranche of its previously announced $40 million Series B financing. The Company plans to allocate all proceeds to continue the development for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia. CAD-9303 is currently being evaluated in the Affinity-1 trial, a multicenter, randomized, placebo-controlled study. “The successful completion of our Series B financing signifies the continued support we have from our current investors and their belief in our programs,” said Jodie Morrison, Chief Executive Officer of Cadent Therapeutics. “We will be using these proceeds to advance our CAD-9303 program, which has continued to enroll patients despite the ongoing COVID-19 pandemic. This program has the potential to transform the lives of patients with schizophrenia and other cognitive deficits. With the close of this tranche, we now have sufficient cash runway into the second quarter of 2021.”

Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia

By |2020-03-10T12:24:03+00:00March 10th, 2020|

CAMBRIDGE, Mass., March 10, 2020 – Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed for its Investigational New Drug (IND) application for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia. Dosing of patients is now underway in the Phase 1 clinical trial. “This IND clearance and initiation of dosing represents a critical milestone for Cadent as we progress CAD-9303 forward as the first drug candidate in our psychiatric disorders pipeline,” stated Jodie Morrison, Chief Executive Officer. “CAD-9303 serves as the first NMDA PAM to be developed to potentially transform the lives of patients with schizophrenia.”

Cadent Therapeutics to Present at the Cowen 40th Annual Health Care Conference

By |2020-02-26T13:03:00+00:00February 26th, 2020|

CAMBRIDGE, Mass., February 26, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 4:00-4:25 pm ET at the Boston Marriott Copley Place.

Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

By |2020-02-19T21:06:47+00:00February 19th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:45 pm ET at the Lotte New York Palace.

Cadent Therapeutics Announces Poster Presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

By |2020-02-06T21:10:17+00:00February 6th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the Company's Cadence-1 study will be highlighted in a poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.

Cadent Therapeutics Announces FDA acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

By |2020-01-24T19:44:31+00:00January 23rd, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883...